LATE TOXICITIES, LONG-TERM FOLLOW-UP, LESS INTENSIVE TREATMENT - LEADING ISSUES IN THE THERAPY OF TESTIS CANCER

被引：10

作者：

KANTOFF, PW

GARNICK, MB

机构：

来源：

JOURNAL OF CLINICAL ONCOLOGY | 1988年 / 6卷 / 08期

关键词：

D O I：

10.1200/JCO.1988.6.8.1216

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1216 / 1219

页数：4

共 28 条

[1]

ANTMAN K, 1988, P AN M AM SOC CLIN, V7, P160

[2] COMPARISON OF CRITERIA FOR ASSIGNING GERM-CELL TUMOR PATIENTS TO GOOD RISK AND POOR RISK STUDIES [J].

BAJORIN, D ;

KATZ, A ;

CHAN, E ;

GELLER, N ;

VOGELZANG, N ;

BOSL, GJ .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (05) :786-792

[3] PROGNOSTIC FACTORS FOR FAVORABLE OUTCOME IN DISSEMINATED GERM-CELL TUMORS [J].

BIRCH, R ;

WILLIAMS, S ;

CONE, A ;

EINHORN, L ;

ROARK, P ;

TURNER, S ;

GRECO, FA .

JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) :400-407

[4] LATE RECURRENCE OF TESTICULAR CANCER [J].

BORGE, N ;

FOSSA, SD ;

OUS, S ;

STENWIG, AE ;

LIEN, HH .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) :1248-1253

[5]

BOSL GJ, 1983, CANCER RES, V43, P3403

[6] A RANDOMIZED TRIAL OF ETOPOSIDE + CISPLATIN VERSUS VINBLASTINE + BLEOMYCIN + CISPLATIN + CYCLOPHOSPHAMIDE + DACTINOMYCIN IN PATIENTS WITH GOOD-PROGNOSIS GERM-CELL TUMORS [J].

BOSL, GJ ;

GELLER, NL ;

BAJORIN, D ;

LEITNER, SP ;

YAGODA, A ;

GOLBEY, RB ;

SCHER, H ;

VOGELZANG, NJ ;

AUMAN, J ;

CAREY, R ;

FAIR, WR ;

HERR, H ;

MORSE, M ;

SOGANI, P ;

WHITMORE, W .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (08) :1231-1238

[7]

COOPER K, 1988, P AN M AM SOC CLIN, V7, P132

[8]

DIMARTINO N, 1988, P AN M AM SOC CLIN, V7, P52

[9] CIS-DIAMMINEDICHLOROPLATINUM, VINBLASTINE, AND BLEOMYCIN COMBINATION CHEMOTHERAPY IN DISSEMINATED TESTICULAR CANCER [J].

EINHORN, LH ;

DONOHUE, J .

ANNALS OF INTERNAL MEDICINE, 1977, 87 (03) :293-298

[10]

EINHORN LH, 1988, P ASCO, V7, P120

← 1 2 3 →